Stay updated with breaking news from Nasdaq Elym. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eliem Therapeutics (NASDAQ:ELYM – Get Rating) is one of 942 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Eliem Therapeutics to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk. Analyst Ratings This is a breakdown […]
Zacks Investment Research upgraded shares of Eliem Therapeutics (NASDAQ:ELYM – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Zacks, “Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet […]
Eliem Therapeutics (NASDAQ:ELYM – Get Rating) announced its quarterly earnings data on Monday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.22, MarketWatch Earnings reports. Shares of NASDAQ:ELYM opened at $9.56 on Wednesday. The company has a 50 day moving average price of $9.41. Eliem […]